Industry News
Excerpt from the Article: BC Children’s Hospital is pleased to congratulate the recipients of the 2020 BCCHR Studentships and Fellowships. These awards give exceptional trainees the opportunity to pursue leading-edge child health research projects under the supervision of BC Children’s Hospital Investigators. BCCHR Studentships and Fellowships are made possible through the support of BC Children’s…
Read MoreExcerpt from the Press Release: Burlingame, CA, August 10, 2020 – Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that the Brazilian regulatory agency, Anvisa, has granted permission to commence a Phase…
Read MoreExcerpt from the article: Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy. “GIGA-2050 is a mix of 12,500 different antibody sequences…
Read MoreExcerpt from the Article: “In April, San Diego’s Dexcom saw a slowdown in patients signing up for its continuous glucose monitors as consumers hunkered down and doctors transitioned to tele-medicine because of the COVID-19 pandemic. The question was how long would the dip last? As it turned out, not very long. As physicians and patients…
Read MoreExcerpt from the Press Release: BOSTON, July 29, 2020 /PRNewswire/ — Samus Therapeutics, Inc., a privately held, biopharmaceutical company developing small molecule epichaperome inhibitors , today announced the presentation of safety and pharmacokinetic data from the Company’s recently completed PU-AD healthy volunteer Phase 1 study at the Alzheimer’s Association International Conference (AAIC 2020). PU-AD is Samus’…
Read MoreExcerpt from the Article: “San Diego start-up Truvian Sciences has received federal emergency approval for a blood test that detects COVID-19 antibodies in as little as 10 minutes. Called Easy Check, the portable test will be sold by Truvian to health professionals for about $15 and has an accuracy rate in excess of 98 percent,…
Read MoreExcerpt from the Press Release: “FOSTER CITY, Calif. & SHANGHAI–(BUSINESS WIRE)–Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat liver disease and cancer, today announced positive results from its completed Phase 1 single ascending dose and multiple ascending dose study of TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor,…
Read MoreExcerpt from the article: “Inovio’s stock climbed as much as 15% in pre-market trading Thursday after the Montgomery County biopharmaceutical company announced its Covid-19 vaccine candidate was effective in protecting non-human primates from the virus 13 weeks after the last vaccination. The stock was up more than 6% to $20.73 per share at Thursday’s close.…
Read MoreExcerpt from the article: “A single-shot vaccine for COVID-19 being developed by a group of scientists, led by Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan H. Barouch, has proven successful in tests on primates and could begin phase 3 trials as early as September. The results of the tests on the vaccine, developed at…
Read MoreExcerpt from the Press Release: “SAN DIEGO–(BUSINESS WIRE)–Selva Therapeutics, Inc. announced today that the company has raised $3 million in a Series A financing round from private investors. The proceeds of the financing will be used to rapidly advance SLV213 into clinical trials as a leading oral drug candidate for the treatment of COVID-19, the…
Read More